Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Vimta Labs Earnings Call: Key Takeaways

Vimta Labs reported Q4 FY26 revenue of ₹1,120M (+16.6% YoY) and FY26 revenue of ₹4,163M (+19.5% YoY). Strategy focuses on core pharma/food testing and entry into biologics.

Highlights
Revenue growthFY26 total income grew 19.5% YoY to INR 4,163 million.
MarginsFY26 EBITDA margin 35.8%; expected to remain stable despite cost pressures.
Demand visibilityStrong visibility in pharma, food, and electronics testing verticals.
Management confidenceHigh; targets 20-25% CAGR and maintaining >35% EBITDA margins.

Growth

FY26 PAT at ₹775M (+16.1% YoY) with healthy EBITDA margins of 35.8%.

Outlook

Targeting 20-25% CAGR; FY27 focuses on biologics execution and US subsidiary operationalization.

Risks

Geopolitical tensions impacting supply chains, rising input costs, and industry-wide talent attrition.

Source

Earnings Call filed with NSE, NSE: VIMTALABS. Summary written with AI assistance from the document.

Read the document ↗

Vimta Labs Ltd: key numbers

Share price
₹599.30
Market cap
₹2,679 Cr
Revenue (annual)
₹407.3 Cr
Net profit (annual)
₹77.51 Cr
P/E (TTM)
33.6×Sector 57.8×
Promoter holding
35.67%-0.18% QoQ
FII holding
4.41%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Vimta Labs Ltd

All →
15:47 IST BSE
Employee Stock Options

Vimta Labs Employee Stock Options

Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.

19:06 IST BSE
Credit Rating

Vimta Labs Credit Rating

CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.